{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:40:58Z","timestamp":1792644058588,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010265","name":"Guizhou Medical University","doi-asserted-by":"publisher","award":["GMUSKL-202531"],"award-info":[{"award-number":["GMUSKL-202531"]}],"id":[{"id":"10.13039\/501100010265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017957","name":"Health Commission of Guizhou Province","doi-asserted-by":"publisher","award":["GZWKJ2022-464"],"award-info":[{"award-number":["GZWKJ2022-464"]}],"id":[{"id":"10.13039\/100017957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010828","name":"Department of Education of Guizhou Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["CXPTXM[2025]021"],"award-info":[{"award-number":["CXPTXM[2025]021"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["KXJZ[2025]014"],"award-info":[{"award-number":["KXJZ[2025]014"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307026"],"award-info":[{"award-number":["22307026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.118923","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:17:11Z","timestamp":1779380231000},"page":"118923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of highly potent and efficacious Bromodomain and Extra-terminal (BET) degraders with activity against acute myeloid leukemia and triple-negative breast cancer"],"prefix":"10.1016","volume":"320","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-8932","authenticated-orcid":false,"given":"Fei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianggui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanju","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-9106","authenticated-orcid":false,"given":"Xiangchun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118923_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000536152","article-title":"Pathophysiology of Acute Myeloid leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ejmech.2026.118923_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.27561","article-title":"Outcomes of patients with treated secondary acute Myeloid leukemia: a high-risk subtype that warrants an independent prognostic designation","volume":"100","author":"Senapati","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.118923_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122164","article-title":"Epigenetic therapies in triple-negative breast cancer: concepts, visions, and challenges","volume":"16","author":"Lehmann","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118923_bib4","article-title":"Current treatment landscape for early triple-negative breast cancer (TNBC)","volume":"12","author":"Lee","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2026.118923_bib5","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1021\/acs.jmedchem.3c01837","article-title":"Structure-Guided design and synthesis of Pyridinone-Based selective bromodomain and extra-terminal domain (BET)-First bromodomain (BD1) inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib6","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting bromodomain and extraterminal proteins for drug discovery: from Current progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib7","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1021\/acs.jmedchem.2c01638","article-title":"Recent advances on small-molecule bromodomain-containing histone acetyltransferase inhibitors","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.621093","article-title":"Safety and efficacy of Bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic Study of clinical trials","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118923_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102323","article-title":"Bromodomain inhibitors and therapeutic applications","volume":"75","author":"Gajjela","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118923_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-023-00127-1","article-title":"Targeting bromodomain-containing proteins: research advances of drug discovery","volume":"4","author":"Pan","year":"2023","journal-title":"Molecular Biomedicine"},{"key":"10.1016\/j.ejmech.2026.118923_bib11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.2019002922","article-title":"Mechanistic basis and efficacy of targeting the \u03b2-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors","volume":"135","author":"Saenz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118923_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41594-024-01384-6","article-title":"Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity","volume":"32","author":"Zhang","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118923_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118923_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118923_bib15","article-title":"Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118923_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.3384","article-title":"The BET protein inhibitor apabetalone (RVX-208) restores angiogenic response in type 1 and type 2 diabetes by transcriptional regulation of thrombospondin-1","volume":"42","author":"Mohammed","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2026.118923_bib17","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1021\/acs.jmedchem.0c00628","article-title":"Discovery of N-Ethyl-4- 2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl -6-methyl-7-oxo-1H-pyrrolo 2,3-c pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain","volume":"63","author":"Sheppard","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib18","doi-asserted-by":"crossref","first-page":"23676","DOI":"10.1021\/acs.jmedchem.5c01911","article-title":"Expanding the scope of PROTACs: opportunities and challenges in topical delivery","volume":"68","author":"Gioiello","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118923_bib20","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1039\/D5CC05563F","article-title":"Targeted degradation of BRD4 by PROTACs: advances in cancer therapy","volume":"62","author":"Hong","year":"2026","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118923_bib21","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-18-2437","article-title":"Overcoming BET inhibitor resistance in malignant peripheral nerve sheath tumors","volume":"25","author":"Cooper","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118923_bib22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1021\/acs.jmedchem.4c02709","article-title":"Evaluation of cereblon-directing warheads for the development of orally bioavailable PROTACs","volume":"68","author":"Actis","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A050","article-title":"Effectiveness of PROTAC BET degraders ARV-825 and ARV-771 in combating chemoresistance in HNSCC","volume":"24","author":"Luffman","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118923_bib24","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1021\/acs.jmedchem.3c00520","article-title":"Precise conformational control yielding highly potent and exceptionally selective BRD4 degraders with strong antitumor activity","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib25","article-title":"Chaperone-mediated protein degradation (CHAMP): a novel technology for tumor-targeted protein degradation","volume":"81","author":"Vandenberg","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118923_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113953","article-title":"Discovery of 1-(5-(1H-benzo d imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy","volume":"227","author":"Kong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib27","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1021\/acs.jmedchem.1c01119","article-title":"4-Acyl pyrrole capped HDAC inhibitors: a new scaffold for hybrid inhibitors of BET proteins and histone deacetylases as antileukemia drug leads","volume":"64","author":"Sch\u00e4ker-H\u00fcbner","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118923_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/2326-6066.CIR-19-0744","article-title":"SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an Anti-PD-1-Resistant model of non-small cell lung cancer","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejmech.2026.118923_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118923_bib31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118923_bib32","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","article-title":"The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118923_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-024-07403-w","article-title":"BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436","volume":"208","author":"Teufelsbauer","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2026.118923_bib34","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1021\/acs.jmedchem.5c00679","article-title":"Discovery and optimization of potent PROTAC degraders of phosphoinositide 3-Kinase with significant in vivo anticancer efficacy","volume":"68","author":"Peng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17460441.2025.2490248","article-title":"Advancing target validation with PROTAC technology","volume":"20","author":"Spitz","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118923_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC technology: from drug development to probe technology for target deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib37","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/acs.jmedchem.5c03024","article-title":"Unhooking the hook: optimization of the Aurora A targeting PROTAC JB170 to CCT400028, an In vitro degrader chemical probe","volume":"69","author":"O'Hanlon","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib38","first-page":"132","article-title":"Comparative analysis of the effect of sex and Age on the hematological and biochemical profile of BALB\/c and C57BL\/6 inbred mice","volume":"64","author":"Patel","year":"2025","journal-title":"JAALAS"},{"key":"10.1016\/j.ejmech.2026.118923_bib39","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1021\/acs.orglett.9b01326","article-title":"Chemoselective synthesis of lenalidomide-based PROTAC Library using alkylation reaction","volume":"21","author":"Qiu","year":"2019","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.118923_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112426","article-title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery","volume":"200","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118923_bib41","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/tcr.201800074","article-title":"Bromodomain drug discovery - the past, the present, and the future","volume":"18","author":"Pervaiz","year":"2018","journal-title":"Chem. Rec."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:22:57Z","timestamp":1792642977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"alternative-id":["S0223523426003685"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118923","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of highly potent and efficacious Bromodomain and Extra-terminal (BET) degraders with activity against acute myeloid leukemia and triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118923"}}